RU2019138773A3 - - Google Patents

Download PDF

Info

Publication number
RU2019138773A3
RU2019138773A3 RU2019138773A RU2019138773A RU2019138773A3 RU 2019138773 A3 RU2019138773 A3 RU 2019138773A3 RU 2019138773 A RU2019138773 A RU 2019138773A RU 2019138773 A RU2019138773 A RU 2019138773A RU 2019138773 A3 RU2019138773 A3 RU 2019138773A3
Authority
RU
Russia
Application number
RU2019138773A
Other languages
Russian (ru)
Other versions
RU2019138773A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019138773A publication Critical patent/RU2019138773A/ru
Publication of RU2019138773A3 publication Critical patent/RU2019138773A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2019138773A 2017-05-05 2018-05-07 Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций RU2019138773A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
US62/501,984 2017-05-05
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Publications (2)

Publication Number Publication Date
RU2019138773A RU2019138773A (ru) 2021-06-08
RU2019138773A3 true RU2019138773A3 (enExample) 2022-02-01

Family

ID=64016742

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019138773A RU2019138773A (ru) 2017-05-05 2018-05-07 Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций

Country Status (11)

Country Link
US (5) US10611787B2 (enExample)
EP (3) EP3618827B1 (enExample)
JP (4) JP7183253B2 (enExample)
CN (2) CN117462558A (enExample)
AU (2) AU2018263965B2 (enExample)
CA (1) CA3062369A1 (enExample)
ES (1) ES2959891T3 (enExample)
PL (1) PL3618827T3 (enExample)
RU (1) RU2019138773A (enExample)
SG (1) SG11201910043PA (enExample)
WO (1) WO2018204930A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
DE10103565B4 (de) * 2001-01-26 2007-06-14 Faustus Forschungs Cie. Translational Cancer Research Gmbh Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
ES2441262T3 (es) 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
EP2509599B1 (en) * 2009-12-11 2014-08-13 Niiki Pharma Inc. Method for treating pancreatic cancer
JP5826259B2 (ja) 2010-06-22 2015-12-02 フイルメニツヒ ソシエテ アノニムFirmenich Sa ルテニウムベース錯体
WO2012012305A2 (en) 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
US10766915B2 (en) 2013-03-15 2020-09-08 Sherri Ann McFARLAND Metal-based coordination complexes as photodynamic compounds and their use
CN103601759B (zh) 2013-10-18 2015-08-19 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌(iii)络合物的制备方法
US10342801B2 (en) * 2015-06-23 2019-07-09 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof

Also Published As

Publication number Publication date
EP4245305A2 (en) 2023-09-20
EP3618827C0 (en) 2023-07-26
US20180327435A1 (en) 2018-11-15
EP4245305A3 (en) 2023-10-04
SG11201910043PA (en) 2019-11-28
EP3618827A4 (en) 2020-09-02
EP4245305C0 (en) 2025-10-08
RU2019138773A (ru) 2021-06-08
ES2959891T3 (es) 2024-02-28
AU2018263965A1 (en) 2019-11-21
JP7183253B2 (ja) 2022-12-05
JP7698083B2 (ja) 2025-06-24
US12415825B2 (en) 2025-09-16
WO2018204930A1 (en) 2018-11-08
US20200262855A1 (en) 2020-08-20
JP7433402B2 (ja) 2024-02-19
US20210277040A1 (en) 2021-09-09
EP4635503A2 (en) 2025-10-22
PL3618827T3 (pl) 2024-01-22
US11739111B2 (en) 2023-08-29
JP2023016867A (ja) 2023-02-02
US10611787B2 (en) 2020-04-07
JP2024045436A (ja) 2024-04-02
EP3618827A1 (en) 2020-03-11
EP4635503A3 (en) 2025-10-29
CN111372939A (zh) 2020-07-03
US20230357297A1 (en) 2023-11-09
CN111372939B (zh) 2023-11-07
US20260042792A1 (en) 2026-02-12
JP2020518676A (ja) 2020-06-25
CA3062369A1 (en) 2018-11-08
AU2018263965B2 (en) 2024-02-29
AU2024203511A1 (en) 2024-06-20
EP3618827B1 (en) 2023-07-26
AU2024203511B2 (en) 2026-03-19
JP2025123344A (ja) 2025-08-22
CN117462558A (zh) 2024-01-30
EP4245305B1 (en) 2025-10-08
US11040993B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
BR122021000189A2 (enExample)
BR112019008823A2 (enExample)
BR112020006084A8 (enExample)
BR112019025875B1 (pt) Sistema de cilindro com estrutura de ocupação de movimento relativo
BR112020011860B1 (pt) Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho
BR112020006283B1 (pt) Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico
BR112020009729B1 (pt) Inibidores de acss2 e métodos de uso dos mesmos
BR112020008714B1 (pt) Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
BR112020006992B1 (pt) Dispositivo de recolhimento e método para o recolhimento de uma embarcação
BR112019023976B1 (pt) Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde
BR112020003314B1 (pt) Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica
BR112020002577B1 (pt) Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo
BR112020003569B1 (pt) Método e disposição para transmissão de dados comutados por pacote entre dispositivos de emissão e recepção marítimos para uma embarcação marítima e dispositivos de emissão e recepção terrestres por interfaces aéreas
BR112020000320B1 (pt) Dispositivo bioerodível de administração de fármacos, seu método de preparação, e uso de uma folha não-tecido
BR112019016885B1 (pt) Remodelagem de imagem integrada e codificação de vídeo
BR112019027876B1 (pt) Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações
BR112020001354B1 (pt) Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel
BR112019026818B1 (pt) Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador
BR102018011961B1 (pt) Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social
BR112019026880B1 (pt) Método de comunicação, método para receber dados, e, dispositivo
BR112019024244B1 (pt) Processos de fermentação de metano de alta produtividade
BR112019023944B1 (pt) Combinação farmacêutica para o tratamento de um câncer
BR112019021396B1 (pt) Processo para fabricação de pululano
BR102018003507B1 (pt) Sistema de isolamento de tensão de tambor de guincho
BR112019016182B1 (pt) Método para diagnosticar risco de revisão relacionado a implante